These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 24703161)

  • 1. MicroRNA let-7a-3 gene methylation is associated with karyotyping, CEBPA promoter methylation, and survival in acute myeloid leukemia.
    Ko YC; Fang WH; Lin TC; Hou HA; Chen CY; Tien HF; Lin LI
    Leuk Res; 2014 May; 38(5):625-31. PubMed ID: 24703161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined testing for CCAAT/enhancer-binding protein alpha (CEBPA) mutations and promoter methylation in acute myeloid leukemia demonstrates shared phenotypic features.
    Szankasi P; Ho AK; Bahler DW; Efimova O; Kelley TW
    Leuk Res; 2011 Feb; 35(2):200-7. PubMed ID: 20970189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Let-7a-3 hypomethylation is associated with favorable/intermediate karyotypes but not with survival in acute myeloid leukemia.
    Zhu XW; Yao DM; Wu DH; Wen XM; Yang J; Guo H; Yang L; Deng ZQ; Zhang YY; Qian W; Lin J; Qian J
    Tumour Biol; 2016 Jan; 37(1):491-501. PubMed ID: 26227220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemia.
    Lin TC; Hou HA; Chou WC; Ou DL; Yu SL; Tien HF; Lin LI
    Leukemia; 2011 Jan; 25(1):32-40. PubMed ID: 20927134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpressed let-7a-3 is associated with poor outcome in acute myeloid leukemia.
    Li Y; Lin J; Yang J; Qian J; Qian W; Yao DM; Deng ZQ; Liu Q; Chen XX; Xie D; An C; Tang CY
    Leuk Res; 2013 Dec; 37(12):1642-7. PubMed ID: 24138945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of promoter DNA methylation and expression levels of genes encoding CCAAT/enhancer binding proteins in AML patients.
    Musialik E; Bujko M; Kober P; Grygorowicz MA; Libura M; Przestrzelska M; Juszczyński P; Borg K; Florek I; Jakóbczyk M; Baranowska A; Siedlecki JA
    Leuk Res; 2014 Jul; 38(7):850-6. PubMed ID: 24878001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normal karyotype acute myeloid leukemia with the CD7+ CD15+ CD34+ HLA-DR + immunophenotype is a clinically distinct entity with a favorable outcome.
    Iriyama N; Asou N; Miyazaki Y; Yamaguchi S; Sato S; Sakura T; Maeda T; Handa H; Takahashi M; Ohtake S; Hatta Y; Sakamaki H; Honda S; Taki T; Taniwaki M; Miyawaki S; Ohnishi K; Kobayashi Y; Naoe T
    Ann Hematol; 2014 Jun; 93(6):957-63. PubMed ID: 24441947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant methylation of CCAAT/enhancer binding protein zeta promoter in acute myeloid leukemia.
    Yao DM; Qian J; Lin J; Wang YL; Chen Q; Qian Z; Li Y; Wang CZ; Yang J
    Leuk Res; 2011 Jul; 35(7):957-60. PubMed ID: 21106240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis.
    Lu L; Katsaros D; de la Longrais IA; Sochirca O; Yu H
    Cancer Res; 2007 Nov; 67(21):10117-22. PubMed ID: 17974952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency and prognostic impact of CEBPA proximal, distal and core promoter methylation in normal karyotype AML: a study on 623 cases.
    Fasan A; Alpermann T; Haferlach C; Grossmann V; Roller A; Kohlmann A; Eder C; Kern W; Haferlach T; Schnittger S
    PLoS One; 2013; 8(2):e54365. PubMed ID: 23383300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complexity of miR-223 regulation by CEBPA in human AML.
    Eyholzer M; Schmid S; Schardt JA; Haefliger S; Mueller BU; Pabst T
    Leuk Res; 2010 May; 34(5):672-6. PubMed ID: 20018373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
    Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
    Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of CEBPA Mutations and Polymorphisms and their Prognostic Relevance in De Novo Acute Myeloid Leukemia Patients.
    Sarojam S; Raveendran S; Vijay S; Sreedharan J; Narayanan G; Sreedharan H
    Asian Pac J Cancer Prev; 2015; 16(9):3785-92. PubMed ID: 25987038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylation status of CEBPA gene promoter in chronic myeloid leukemia.
    Annamaneni S; Kagita S; Gorre M; Digumarti RR; Satti V; Battini MR
    Hematology; 2014 Jan; 19(1):42-4. PubMed ID: 23541085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis.
    Fasan A; Eder C; Haferlach C; Grossmann V; Kohlmann A; Dicker F; Kern W; Haferlach T; Schnittger S
    Leukemia; 2013 Feb; 27(2):482-5. PubMed ID: 22814295
    [No Abstract]   [Full Text] [Related]  

  • 16. K313dup is a recurrent CEBPA mutation in de novo acute myeloid leukemia (AML).
    Carnicer MJ; Lasa A; Buschbeck M; Serrano E; Carricondo M; Brunet S; Aventin A; Sierra J; Di Croce L; Nomdedeu JF
    Ann Hematol; 2008 Oct; 87(10):819-27. PubMed ID: 18587575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deficient CEBPA DNA binding function in normal karyotype AML patients is associated with favorable prognosis.
    Fos J; Pabst T; Petkovic V; Ratschiller D; Mueller BU
    Blood; 2011 May; 117(18):4881-4. PubMed ID: 21389317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promoter hypermethylation of let-7a-3 is relevant to its down-expression in diabetic nephropathy by targeting UHRF1.
    Peng R; Liu H; Peng H; Zhou J; Zha H; Chen X; Zhang L; Sun Y; Yin P; Wen L; Wu T; Zhang Z
    Gene; 2015 Oct; 570(1):57-63. PubMed ID: 26049093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia.
    Hollink IH; van den Heuvel-Eibrink MM; Arentsen-Peters ST; Zimmermann M; Peeters JK; Valk PJ; Balgobind BV; Sonneveld E; Kaspers GJ; de Bont ES; Trka J; Baruchel A; Creutzig U; Pieters R; Reinhardt D; Zwaan CM
    Haematologica; 2011 Mar; 96(3):384-92. PubMed ID: 21134981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fragment length analysis screening for detection of CEBPA mutations in intermediate-risk karyotype acute myeloid leukemia.
    Fuster O; Barragán E; Bolufer P; Such E; Valencia A; Ibáñez M; Dolz S; de Juan I; Jiménez A; Gómez MT; Buño I; Martínez J; Cervera J; Montesinos P; Moscardó F; Sanz MÁ
    Ann Hematol; 2012 Jan; 91(1):1-7. PubMed ID: 21538063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.